戻る 戻る
細胞番号 : 細胞名
RCB1005 : KP4  update : 2023/04/03
細胞特性(Comment:英)Pancreatic ductal cell carcinoma. Mother cell line of KP4-1, -2, and -3.
細胞特性(日)日本人膵管上皮由来の膵管癌。高カルシウム血症を誘発するPTHrPを産生する。KP4-1, 4-2, 4-3の親株。
使用条件(英)There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Nishi, Y. & Nawata, H.
樹立者 Nawata, H. & Nishi, Y.
寄託日 1994
動物種 human < Mammals
属名 Homo
種名 sapiens
人種 Japanese
性別 Male
50 years
採取組織 pancreas, ascites meta
病名 pancreatic ductal cell carcino
転移 Yes
転移巣 liver, lung, etc
細胞分類 cancer
初代培養日 1990
入手歴 Direct from originator.
メモ_1 Mycoplasma was eliminated with MC-210 by the depositor.
細胞寿命 infinite
細胞形態 epithelial-like
Cellosaurus(Expasy) CVCL_1338
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Adherent cells
培地 DMEM/HamF12 + 10% FBS
抗生物質 Free
継代方法 0.25% Trypsin
継代密度 1 : 8 split
継代・培地交換頻度 Subculture : 1-2 times/week, Medium Renewal : 2 times/week
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
アイソザイム検査 LD, NP
染色体検査 62-174(50) : /64(6),65(6),67(8),69(6),70(5),71(2)/
個体識別検査 OK
D5S818 D13S317 D7S820 D16S539 vWA TH01 Amelogenin TPOX CSF1PO
10,12 10 10,11 10 14 9,10 X 9,11 10,12
文献情報 Reference(英) 1件
Reference(日) 1件
利用者成果(英) 43件
利用者成果(日) 1件

1840  Nishi, Y., Haji, M., Takayanagi, R., Iguchi, H., Shimazoe, T., Hirata, J., and Nawata, H.  Establishment and characterization of PTHrP-producing human pancreatic cancer cell line  Int J Oncol  1994  5:33-39  PubMed ID: 21559554  

2151  井口東郎、西芳寛、名和田新、若杉英之  消化器癌における高カルシウム血症  病理と臨床  1996  14:305-308   

21084  Kano MT, Kokuryo T, Baba T, Yamazaki K, Yamaguchi J, Sunagawa M, Ogura A, Watanabe N, Onoe S, Miyata K, Mizuno T, Uehara K, Igami T, Yokoyama Y, Ebata T, Nagino M.  Cyclodextrin Conjugated α-Bisabolol Suppresses FAK Phosphorylation and Induces Apoptosis in Pancreatic Cancer.  Anticancer Res  2023  43(3):1009-1016  PubMed ID: 36854520   DOI: 10.21873/anticanres.16245
20773  Han JH, Kim YK, Kim H, Lee J, Oh MJ, Kim SB, Kim M, Kim KH, Yoon HJ, Lee MS, Minna JD, White MA, Kim HS.  Snail acetylation by autophagy-derived acetyl-coenzyme A promotes invasion and metastasis of KRAS-LKB1 co-mutated lung cancer cells.  Cancer Commun (Lond)  2022    PubMed ID: 35838183   DOI: 10.1002/cac2.12332
20090  Minami F, Sasaki N, Shichi Y, Gomi F, Michishita M, Ohkusu-Tsukada K, Toyoda M, Takahashi K, Ishiwata T.  Morphofunctional analysis of human pancreatic cancer cell lines in 2- and 3-dimensional cultures.  Sci Rep  2021  11(1):6775  PubMed ID: 33762591   DOI: 10.1038/s41598-021-86028-1
20100  Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook GS, Hong DS, Girard P, El Bawab S.  Translational Pharmacokinetic-pharmacodynamic Modelling of Preclinical and Clinical Data of the Oral MET Inhibitor Tepotinib to Determine the Recommended Phase II Dose.  CPT Pharmacometrics Syst Pharmacol  2021    PubMed ID: 33818908   DOI: 10.1002/psp4.12602
20106  Neijssen J, Cardoso RMF, Chevalier KM, Wiegman L, Valerius T, Anderson GM, Moores SL, Schuurman J, Parren PWHI, Strohl WR, Chiu ML.  Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.  J Biol Chem  2021  100641  PubMed ID: 33839159   DOI: 10.1016/j.jbc.2021.100641
20189  Suzuki M, Anko M, Ohara M, Matsumoto KI, Hasegawa S.  Radiation-Induced Autophagy in Human Pancreatic Cancer Cells is Critically Dependent on G2 Checkpoint Activation: A Mechanism of Radioresistance in Pancreatic Cancer.  Int J Radiat Oncol Biol Phys  2021    PubMed ID: 34112559   DOI: 10.1016/j.ijrobp.2021.04.001
16211  Shyla Gopalakrishnan, Soumya Krishnan Uma, Gayathri Mohan, Amrutha Mohan, Geetha Shanmugam, Vineeth T. V. Kumar, Sreekumar J, Sivakumar K. Chandrika, Dileep Vasudevan, Sai Ravi Chandra Nori, Shijulal Nelson Sathi, Sanil George, Tessy Thomas Maliekal  SSTP1, a Host Defense Peptide, Exploits the Immunomodulatory IL6 Pathway to Induce Apoptosis in Cancer Cells  Front Immunol  2021  12:740620  PubMed ID: 34867962   DOI: 10.3389/fimmu.2021.740620
13240  Onodera T, Momose I, Adachi H, Yamazaki Y, Sawa R, Ohba SI, Kawada M.  Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition.  J Biol Chem  2020    PubMed ID: 32978257   DOI: 10.1074/jbc.RA120.013893
13287  Sasaki N, Gomi F, Yoshimura H, Yamamoto M, Matsuda Y, Michishita M, Hatakeyama H, Kawano Y, Toyoda M, Korc M, Ishiwata T.  FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer.  Cancers (Basel)  2020    PubMed ID: 33066597   DOI: 10.3390/cancers12102976
13385  Neggers JE, Paolella BR, Asfaw A, Rothberg MV, Skipper TA, Yang A, Kalekar RL, Krill-Burger JM, Dharia NV, Kugener G, Kalfon J, Yuan C, Dumont N, Gonzalez A, Abdusamad M, Li YY, Spurr LF, Wu WW, Durbin AD, Wolpin BM, Piccioni F, Root DE, Boehm JS, Cherniack AD, Tsherniak A, Hong AL, Hahn WC, Stegmaier K, Golub TR, Vazquez F, Aguirre AJ.  Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.  Cell Rep  2020    PubMed ID: 33326793   DOI: 10.1016/j.celrep.2020.108493
13559  Hu S, Chen X, Xu X, Zheng C, Huang W, Zhou Y, Akuetteh PDP, Yang H, Shi K, Chen B, Zhang Q.  STRAP as a New Therapeutic Target for Poor Prognosis of Pancreatic Ductal Adenocarcinoma Patients Mainly Caused by TP53 Mutation  Front Oncol  2020  10:594224  PubMed ID: 33134183   DOI: 10.3389/fonc.2020.594224
14279  Falchook GS, Kurzrock R, Amin HM, Xiong W, Fu S, Piha-Paul SA, Janku F, Eskandari G, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S, Hong DS.  First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors  Clin Cancer Res  2020  26(6):1237-1246  PubMed ID: 31822497   DOI: 10.1158/1078-0432.CCR-19-2860
14280  Hobbs GA, Baker NM, Miermont AM, Thurman RD, Pierobon M, Tran TH, Anderson AO, Waters AM, Diehl JN, Papke B, Hodge RG, Klomp JE, Goodwin CM, DeLiberty JM, Wang J, Ng RWS, Gautam P, Bryant KL, Esposito D, Campbell SL, Petricoin EF 3rd, Simanshu DK, Aguirre AJ, Wolpin BM, Wennerberg K, Rudloff U, Cox AD, Der CJ.  Atypical KRAS G12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer  Cancer Discov  2020  10(1):104-123  PubMed ID: 31649109   DOI: 10.1158/2159-8290.CD-19-1006
14799  Zenke FT, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin V, Pehl U, Grombacher T, Wilm C, Fuchss T, Amendt C, Vassilev LT, Blaukat A.  Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models  Mol Cancer Ther  2020  19(5):1091-1101.  PubMed ID: 32220971   DOI: 10.1158/1535-7163.MCT-19-0734
15112  Wang Z, Hausmann S, Lyu R, Li TM, Lofgren SM, Flores NM, Fuentes ME, Caporicci M, Yang Z, Meiners MJ, Cheek MA, Howard SA, Zhang L, Elias JE, Kim MP, Maitra A, Wang H, Bassik MC, Keogh MC, Sage J, Gozani O, Mazur PK.  SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy  Cancer Cell  2020  37(6):834-849.e13  PubMed ID: 32442403   DOI: 10.1016/j.ccell.2020.04.014
11511  Behan FM, Iorio F, Picco G, Gonçalves E, Beaver CM, Migliardi G, Santos R, Rao Y, Sassi F, Pinnelli M, Ansari R, Harper S, Jackson DA, McRae R, Pooley R, Wilkinson P, van der Meer D, Dow D, Buser-Doepner C, Bertotti A, Trusolino L, Stronach EA, Saez-Rodriguez J, Yusa K, Garnett MJ.  Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.  Nature  2019    PubMed ID: 30971826   DOI: 10.1038/s41586-019-1103-9
11811  Mohammad GH, Vassileva V, Acedo P, Olde Damink SWM, Malago M, Dhar DK, Pereira SP.  Targeting Pyruvate Kinase M2 and Lactate Dehydrogenase A Is an Effective Combination Strategy for the Treatment of Pancreatic Cancer.  Cancers (Basel)  2019  11(9):1372  PubMed ID: 31527446   DOI: 10.3390/cancers11091372
11831  Sulahian R, Kwon JJ, Walsh KH, Pailler E, Bosse TL, Thaker M, Almanza D, Dempster JM, Pan J, Piccioni F, Dumont N, Gonzalez A, Rennhack J, Nabet B, Bachman JA, Goodale A, Lee Y, Bagul M, Liao R, Navarro A, Yuan TL, Ng RWS, Raghavan S, Gray NS, Tsherniak A, Vazquez F, Root DE, Firestone AJ, Settleman J, Hahn WC, Aguirre AJ.  Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.  Cell Rep  2019    PubMed ID: 31577942   DOI: 10.1016/j.celrep.2019.08.090
14265  Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, Schoeberl B, Pipas JM, Straubinger RM, Askoxylakis V, Lugovskoy AA.  Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer  Clin Cancer Res  2018  24(12):2873-288  PubMed ID: 29549161   DOI: 10.1158/1078-0432.CCR-17-2262
14550  Gonzalez PS, O'Prey J, Cardaci S, Barthet VJA, Sakamaki JI, Beaumatin F, Roseweir A, Gay DM, Mackay G, Malviya G, Kania E, Ritchie S, Baudot AD, Zunino B, Mrowinska A, Nixon C, Ennis D, Hoyle A, Millan D, McNeish IA, Sansom OJ, Edwards J, Ryan KM.  Mannose impairs tumour growth and enhances chemotherapy  Nature  2018  563(7733):719-723  PubMed ID: 30464341   DOI: 10.1038/s41586-018-0729-3
10049  Wong M, Funasaka K, Obayashi T, Miyahara R, Hirooka Y, Hamaguchi M, Goto H, Senga T.  AMPD3 is associated with the malignant characteristics of gastrointestinal stromal tumors.  Oncol Lett  2017  13:1281-1287  PubMed ID: 28454247   DOI: 10.3892/ol.2016.5532
10120  Murata Y, Kokuryo T, Yokoyama Y, Yamaguchi J, Miwa T, Shibuya M, Yamamoto Y, Nagino M.  The Anticancer Effects of Novel α-Bisabolol Derivatives Against Pancreatic Cancer.  Anticancer Res.  2017  37:589-598  PubMed ID: 28179305   DOI: 10.21873/anticanres.11352
10220  Kania E, Pająk B, O'Prey J, Sierra Gonzalez P, Litwiniuk A, Urbańska K, Ryan KM, Orzechowski A.  Verapamil treatment induces cytoprotective autophagy by modulating cellular metabolism.  FEBS J.  2017  284:1370-1387  PubMed ID: 28342290   DOI: 10.1111/febs.14064
11016    Population Pharmacokinetics of Liposomal Irinotecan  CLINICAL PHARMACOLOGY & THERAPEUTICS  2017  102  PubMed ID: 28445610   DOI: 10.1002/cpt.720
14239  Wang J, Anderson MG, Oleksijew A, Vaidya KS, Boghaert ER, Tucker L, Zhang Q, Han EK, Palma JP, Naumovski L, Reilly EB.  ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence  Clin Cancer Res  2017  23(4):992-1000  PubMed ID: 27573171   DOI: 10.1158/1078-0432.CCR-16-1568
14741  Sakamaki JI, Wilkinson S, Hahn M, Tasdemir N, O'Prey J, Clark W, Hedley A, Nixon C, Long JS, New M, Van Acker T, Tooze SA, Lowe SW, Dikic I, Ryan KM.  Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function  Mol Cell   2017  66(4):517-532  PubMed ID: 28525743   DOI: 10.1016/j.molcel.2017.04.027
14760  Kim JW, Abudayyeh OO, Yeerna H, Yeang CH, Stewart M, Jenkins RW, Kitajima S, Konieczkowski DJ, Medetgul-Ernar K, Cavazos T, Mah C, Ting S, Van Allen EM, Cohen O, Mcdermott J, Damato E, Aguirre AJ, Liang J, Liberzon A, Alexe G, Doench J, Ghandi M, Vazquez F, Weir BA, Tsherniak A, Subramanian A, Meneses-Cime K, Park J, Clemons P, Garraway LA, Thomas D, Boehm JS, Barbie DA, Hahn WC, Mesirov JP, Tamayo P.  Decomposing Oncogenic Transcriptional Signatures to Generate Maps of Divergent Cellular States  Cell Syst   2017  5(2):105-118  PubMed ID: 28837809   DOI: 10.1016/j.cels.2017.08.002
7191  Kawakubo K, Ohnishi S, Hatanaka Y, Hatanaka KC, Hosono H, Kubota Y, Kamiya M, Kuwatani M, Kawakami H, Urano Y, Sakamoto N.  Feasibility of Using an Enzymatically Activatable Fluorescence Probe for the Rapid Evaluation of Pancreatic Tissue Obtained Using Endoscopic Ultrasound-Guided Fine Needle Aspiration: a Pilot Study.  Mol Imaging Biol  2016  18:463-71  PubMed ID: 26431952   DOI: 10.1007/s11307-015-0898-5
9663  Tarhan YE, Kato T, Jang M, Haga Y, Ueda K, Nakamura Y, Park JH.  Morphological Changes, Cadherin Switching, and Growth Suppression in Pancreatic Cancer by GALNT6 Knockdown.  Neoplasia  2016  18:265-272  PubMed ID: 27237318   DOI: 10.1016/j.neo.2016.03.005
9977  Sellmann C, Doerner A, Knuehl C, Rasche N, Sood V, Krah S, Rhiel L, Messemer A, Wesolowski J, Schuette M, Becker S, Toleikis L, Kolmar H, Hock B.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.  J. Biol. Chem.  2016  291:25106-25119  PubMed ID: 27694443   DOI: 10.1074/jbc.M116.753491
12674  Kokuryo T, Hibino S, Suzuki K, Watanabe K, Yokoyama Y, Nagino M, Senga T, Hamaguchi M.  Nek2 siRNA therapy using a portal venous port-catheter system for liver metastasis in pancreatic cancer  Cancer Sci   2016  107(9):1315-20  PubMed ID: 27316377   DOI: 10.1111/cas.12993
14130  Marjon K, Cameron MJ, Quang P, Clasquin MF, Mandley E, Kunii K, McVay M, Choe S, Kernytsky A, Gross S, Konteatis Z, Murtie J, Blake ML, Travins J, Dorsch M, Biller SA, Marks KM.  MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis  Cell Rep  2016  15(3):574-587  PubMed ID: 27068473   DOI: 10.1016/j.celrep.2016.03.043
7372  Miwa T, Kokuryo T, Yokoyama Y, Yamaguchi J, Nagino M.  Therapeutic potential of targeting protein for Xklp2 silencing for pancreatic cancer.  Cancer Med  2015  4:1091-100  PubMed ID: 25914189   DOI: 10.1002/cam4.453
15118  Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y.  Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression  Mol Cancer Ther  2015  14(2):533-41  PubMed ID: 25522765   DOI: 10.1158/1535-7163.MCT-14-0456
5018  Tomizawa M, Shinozaki F, Sugiyama T, Yamamoto S, Sueishi M, Yoshida T.  Frizzled-2: A potential novel target for molecular pancreatic cancer therapy.  Oncol Lett  2014  7(1):74-78  PubMed ID: 24348824   DOI: 10.3892/ol.2013.1681
5843  Bladt F, Faden B, Friese-Hamim M, Knuehl C, Wilm C, Fittschen C, Grädler U, Meyring M, Dorsch D, Jaehrling F, Pehl U, Stieber F, Schadt O, Blaukat A.  EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.  Clin Cancer Res  2013  19(11):2941-51  PubMed ID: 23553846   DOI: 10.1158/1078-0432.CCR-12-3247
9175  Dan Cojocari, Ravi N Vellanki, Brandon Sit, David Uehling, Marianne Koritzinsky, Bradly G Wouters  New Small Molecule Inhibitors of UPR Activation Demonstrate That PERK, but Not IRE1α Signaling Is Essential for Promoting Adaptation and Survival to Hypoxia  Radiother Oncol   2013  108 (3), 541-7  PubMed ID: 23830192   DOI: 10.1016/j.radonc.2013.06.005
12868  Yoshida M, Takimoto R, Murase K, Sato Y, Hirakawa M, Tamura F, Sato T, Iyama S, Osuga T, Miyanishi K, Takada K, Hayashi T, Kobune M, Kato J.  Targeting anticancer drug delivery to pancreatic cancer cells using a fucose-bound nanoparticle approach  PLoS One  2012  7(7):e39545  PubMed ID: 22808043   DOI: 10.1371/journal.pone.0039545
7696  Seki T, Kokuryo T, Yokoyama Y, Suzuki H, Itatsu K, Nakagawa A, Mizutani T, Miyake T, Uno M, Yamauchi K, Nagino M.  Antitumor effects of α-bisabolol against pancreatic cancer.  Cancer Sci.  2011  102:2199-205  PubMed ID: 21883695   DOI: 10.1111/j.1349-7006.2011.02082.x
5022  Mitsuno M, Kitajima Y, Ohtaka K, Kai K, Hashiguchi K, Nakamura J, Hiraki M, Noshiro H, Miyazaki K.  Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.  Int J Oncol  2010  36(2):341-9  PubMed ID: 20043067  
5875  Mishra R, Miyamoto M, Yoshioka T, Ishikawa K, Matsumura Y, Shoji Y, Ichinokawa K, Itoh T, Shichinohe T, Hirano S, Kondo S.  Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo.  Int J Oncol  2009  34(5):1231-40  PubMed ID: 19360336  
8748  Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, Carano RA, Kasman I, Mai E, Young J, Zha J, Zhang Z, Ross S, Schwall R, Colbern G, Merchant M.  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.  Cancer Res.  2008  68:4360-8  PubMed ID: 18519697   DOI: 10.1158/0008-5472.CAN-07-5960
3106  Takeda, Ami, Osaki, Mitsuhiko, Adachi, Keiko, Honjo, Soichiro, Ito, Hisao  Role of the phosphatidylinositol 3'-kinase-Akt signal pathway in the proliferation of human pancreatic ductal carcinoma cell lines.  Pancreas  2004  28:353-8  PubMed ID: 15084985   DOI: 10.1097/00006676-200404000-00026

3111  武田安未、尾崎充彦、安達啓子、本城総一郎、井藤久雄  ヒト膵管癌細胞株における抗Fas抗体誘導アポトーシスとFasおよびFas関連因子の発現    米子医学雑誌  2003  54:145-154   

戻る 戻る 理研トップページへ